Table 1.

Tabulation of indications and drug classes

Bevacizumab is listed under angiogenesis inhibitor rather than antibody. Molecular or mechanistic class was determined for each molecule. The number of unique molecules in each drug class is indicated for each time period at the time of initial approval. Stage of cancer treatment was categorized into palliative, advanced/metastatic, local/adjuvant, and prophylactic. The number of indications in each stage is presented for each time period.

^aAfter date of initial approval.